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ABSTRACT
Pyruvate kinase L (PK-L) is a key regulatory enzyme of the hepatic
glycolytic/gluconeogenic pathway that can be dephosphorylated and
activated in response to insulin. However, the signaling cascades
involved in this insulin effect have not been established. In this work
we have investigated the potential involvement of phosphatidylino-
sitol 3-kinase (PI 3-K) and p44/p42 mitogen-activated protein kinase
(MAPK) pathways in the short-term modulation of PK-L by insulin in
primary cultures of rat hepatocytes. Wortmannin, at a concentration
of 100 nM, caused a marked inhibition of the PI 3-K/protein kinase B
pathway, which became complete at 500 nM wortmannin. Likewise,
wortmannin at 100 and 500 nM, elicited partial and total inhibitions
of insulin-mediated activation of PK-L, respectively. However, this PI
3-K inhibitor also reduced insulin-mediated phosphorylation of p44/
p42 MAPK in cultured rat hepatocytes, indicating that both the PI 3-K
and MAPK pathways could be involved in PK-L activation by insulin.
Three facts appear to reinforce this hypothesis: 1) the selective and
complete inhibition of the PI 3-K/protein kinase B pathway by
LY294002 (50 mM) was accompanied by a partial blockade of insulin-
induced PK-L activation; 2) when signaling through the MAPK cas-
cade was selectively suppressed by the presence of PD98059 (50 mM),
a 50% reduction of insulin-induced activation of PK-L was observed;
and 3) the effect of PD98059 (50 mM) on PK-L activation was reinforced
by the additional presence of 100 nM wortmannin. We also observed
that the blockade of p70 S6-kinase by rapamycin did not affect the
activation of PK-L by insulin. From these findings it can be concluded
that both PI 3-K and MAPK pathways, but not p70 S6-kinase, are
involved in the short-term activation of PK-L by insulin in rat hepa-
tocytes. (Endocrinology 142: 1057–1064, 2001)
INSULIN PLAYS a key role in regulating a wide range ofcellular processes, including carbohydrate and lipid me-
tabolism, protein synthesis, and cell growth (1). In recent
years, the molecular mechanisms involved in insulin signal-
ing have been extensively investigated. Thus, insulin recep-
tor undergoes autophosphorylation on tyrosine residues
upon binding of the hormone, which enhances its tyrosine
kinase activity toward different cytosolic proteins, such as
insulin receptor substrates (IRSs) and Shc (1, 2). Tyrosine
phosphorylation of both IRS-1 and IRS-2 causes the activa-
tion of the phosphatidylinositol 3-kinase (PI 3-K)/protein
kinase B (PKB) signaling pathway. This occurs by rapid
recruitment and activation of PI 3-K in the proximity of the
cell membrane, followed by an intracellular increment in
phosphatidylinositol 3,4,5-trisphosphate [PI(3,4,5)P3] con-
centration (3, 4). This metabolite is required for the activation
of PKB (5–7) and may also bind guanine nucleotide exchange
factors, phospholipase Cg, and other cytosolic proteins (4).
There is also evidence that stimulation of PI 3-K is involved
in the activation of p70 S6-kinase (p70 S6-K) by insulin (8).
On the other hand, tyrosine-phosphorylated IRSs and Shc
also interact with SH-2 domains of growth factor receptor-
binding protein 2 (1, 2). This protein binds proline-rich motifs
on SOS through its SH-3 domains, which results in the ac-
tivation of Ras. This is followed by translocation of Raf-1 to
the plasma membrane and activation of the mitogen-acti-
vated protein kinase (MAPK) cascade (9, 10).
The involvement of the above-mentioned signaling cas-
cades in the long- and short-term metabolic effects elicited by
insulin, such as stimulation of glucose transport (11), accel-
eration of both glycogen (12, 13) and protein synthesis (14),
inhibition of lipolysis (15), and repression of both phos-
phoenolpyruvate carboxykinase and glucose 6-phosphatase
gene transcription (16, 17) has been recently established.
However, the signaling pathways involved in the short-term
control of key regulatory steps of hepatic gluconeogenesis by
insulin have not been elucidated. In the liver, the glycolytic/
gluconeogenic pathway is tightly regulated by hormones
such as insulin, glucagon, and epinephrine, acting at both the
fructose 6-P/fructose 1,6-P2 and the phosphoenolpyruvate/
pyruvate substrate cycles (18, 19). In the latter substrate cycle,
the short-term hormonal control is exerted by modulating
PK-L activity. This enzyme is regulated by allosteric effectors
and phosphorylation/dephosphorylation mechanisms. In
the liver, glucagon can elicit the phosphorylation and inac-
tivation of PK-L through the stimulation of a cAMP-depen-
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dent protein kinase (18, 19). Dephosphorylation and re-
activation of PK-L appear to be mediated by protein phos-
phatases 2A and/or 2C (20–22). It is known that insulin may
antagonize the effects of glucagon on PK-L by decreasing the
hepatic concentration of cAMP (18, 19). Furthermore, insulin
may induce the activation of PK-L without significant
changes in the hepatic content of cAMP (19, 23, 24) by a
process in which the dephosphorylation of the enzyme has
been implicated (23–25). In connection with this, it has been
demonstrated that the activation of PK-L by insulin in iso-
lated rat hepatocytes is accompanied by a transient increase
in pyruvate kinase phosphatase activity (22, 25).
In this work we have investigated the potential involve-
ment of PI 3-K/PKB and p44/p42 MAPK [extracellular sig-
nal-regulated kinase 1/2 (ERK-1/ERK-2)] signaling path-
ways as well as p70 S6-K in the insulin-induced activation of
PK-L in primary cultures of rat hepatocytes. Our results
show that the presence of PI 3-K inhibitors, such as wort-
mannin or LY294002, in the incubation medium significantly
reduced the activation of PK-L by insulin. Furthermore,
PD98059 at a concentration that completely blocked insulin
signaling through the MAPK cascade caused a 50% reduction
in insulin-induced activation of PK-L, an effect that was
further reinforced by the additional presence of a suboptimal
concentration of wortmannin. It was also observed that the
blockade of p70 S6-K by rapamycin did not significantly
affect the activation of PK-L by insulin. These results indicate
that both p44/p42 MAPK and PI 3-K signaling pathways, but
not p70 S6-K, are implicated in the short-term regulation of
PK-L by insulin.
Materials and Methods
Reagents
Antibodies against IRS-1 and p85 were obtained from Santa Cruz
Biotechnology, Inc. (Heidelberg, Germany). Mouse antiphosphoty-
rosine and anti-IRS2 antibodies were purchased from Upstate Biotech-
nology, Inc. (Lake Placid, NY). Antibodies against the phosphorylated
forms of p44/p42 MAPK (Thr202/Tyr204), PKB (Ser473 and Thr308), and
p70 S6-K (Thr389) as well as the p44/p42 MAPK antibody were obtained
from New England Biolabs, Inc. (Taunus, Germany). Polyvinylidene
difluoride (PVDF) membranes were purchased from Millipore Corp.
Ibe´rica, SA (Madrid, Spain). Wortmannin and l-a-phosphatidylinositol
were obtained from Sigma (St. Louis, MO). Rapamycin, PD98059, and
LY294002 were purchased from Calbiochem (San Diego, CA). Insulin
was from Novo Industri (Copenhagen, Denmark). Earle’s medium 199
was obtained from ICN Iberica, S.A. (Barcelona, Spain). Collagenase A,
substrates, auxiliary enzymes, and coenzymes were purchased from
Roche Molecular Biochemicals (Mannheim, Germany). [g-32P]ATP (3
Ci/mmol) and enhanced chemiluminescence reagents were provided by
Amersham Pharmacia Biotech (Barcelona, Spain). The remaining re-
agents, all of analytical grade, were obtained from Roche, Sigma, or
Merck & Co., Inc. (Darmstadt, Germany).
Animals
Fed male Wistar rats from our inbred colony were used. The animals
were maintained on standard chow (A.04 Panlab SL, Barcelona, Spain)
and water ad libitum and were housed in animal quarters at constant
temperature (23 C) with a fixed light cycle (12 h). The animal experi-
mentation described has been conducted in accordance with the highest
standards of humane animal care. All animals were anesthetized with
sodium pentobarbital (5 mg/100 g BW) immediately before the
experiments.
Culture conditions and cell incubations
Hepatocytes were isolated by perfusion of the liver with collagenase
(26) and suspended in medium 199 supplemented with 10% FBS, 0.1%
BSA, 1 mm T3, 1 mm dexamethasone, and glucose up to 10 mm. Hepa-
tocytes were plated to attain a cell density of 1.2 3 105 cells/cm2 and
cultured in a cell incubator at 37 C in an atmosphere of 5% CO2. Four
hours after plating, the medium was replaced by fresh supplemented
medium 199. After 19 h of culture, hepatocyte monolayers were washed
three times with PBS and incubated for an additional 2 h in medium 199
supplemented with 20 mm HEPES (pH 7.4), 0.1% BSA, and 10 mm
glucose. Then, cells were treated with insulin for 5 or 10 min, as indi-
cated. Wortmannin, LY294002, and rapamycin were added to the in-
cubation medium 10 min before the addition of insulin, whereas
PD98059 was incorporated into the medium 30 min before the addition
of hormone. Appropriate vehicle controls were included in every
experiment.
Analytical procedures
For the measurement of pyruvate kinase activity, hepatocyte mono-
layers were washed once with ice-cold 0.9% NaCl and immediately
frozen in liquid N2 at the indicated times. Then, cell monolayers were
thawed in a medium containing 50 mm glycylglycine, 15 mm EGTA, and
100 mm potassium fluoride, pH 7.4, and homogenized with a Polytron
PT 1200C (Kinematica AG, Lucerne, Switzerland). After centrifugation
(10,000 3 g for 5 min), pyruvate kinase activity was determined in the
supernatants using a spectrophotometric assay as described by Felı´u et
al. (27). The incubation mixture contained 50 mm glycylglycine (pH 7.4),
0.1 m KCl, 10 mm MgCl2, 1.25 mm Mg-ADP, 0.15 mm NADH, and 1 U
lactate dehydrogenase in a total volume of 1 ml. Aliquots of the super-
natant were added to the mixture and allowed to stand for 10 min at 30
C; the reaction was started by the addition of either 0.15 mm (v0.15) or
5 mm phosphoenolpyruvate (Vmax).
For immunoprecipitations, hepatocytes were washed once with ice-
cold 0.9% NaCl and immediately homogenized in a lysis medium con-
taining 50 mm HEPES (pH 7.4), 10 mm Na4P2O7, 100 mm NaF, 10 mm
EDTA, 1 mm Na3VO4, 1% Triton X-100, 10 mg/ml aprotinin, 5 mg/ml
leupeptin, 2 mm benzamidine, and 2 mm phenylmethylsuflonylfluoride.
Cell lysates were centrifuged (10,000 3 g for 30 min), and the super-
natants were incubated for 3 h with the corresponding antibody. Then,
the immunocomplexes were captured with protein A-agarose (Sigma),
as indicated by the manufacturer. All of these procedures were carried
out at 4 C. PI 3-K activity was assayed in either anti-IRS1 or anti-IRS2
immunoprecipitates by 32P incorporation into phosphatidylinositol (28).
For immunoblotting, cell lysates or immunoprecipitates were sub-
jected to SDS-PAGE. Proteins were transferred to PVDF membranes and
blocked with 5% nonfat dried milk dissolved in a solution (TTBS) con-
taining 20 mm Tris (pH 7.4), 0.05% Tween-20, and 150 mm NaCl. Then,
PVDF membranes were probed with the corresponding antibody and
washed four times (5 min each) with TTBS. Afterward, membranes were
incubated with horseradish peroxidase conjugated to antirabbit or an-
timouse IgG (1:2000). Finally, membranes were washed four times with
TTBS and developed by enhanced chemiluminescence. All immuno-
precipitations, immunoblots, and PI 3-K activity assays were performed
in at least two separate experiments.
Statistical analysis
Where applicable, data are expressed as the mean 6 sem, with n equal
to the number of different experiments. Paired Student’s t test was
performed when two groups were compared. One-way ANOVA with
repeated measures was used, followed by Tukey-Kramer’s test, when
multiple groups were compared (Instat, GraphPad Software, Inc., San
Diego, CA). Differences were considered statistically significant when
P , 0.05.
Results
Activation of PI 3-K by insulin
As expected, insulin elicited a dose-dependent increase in
tyrosine phosphorylation of IRS-1 and IRS-2 in primary cul-
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tured rat hepatocytes (Fig. 1). This was accompanied by a
dose-dependent association of p85 with phosphorylated IRSs
and an activation of PI 3-K. It is of note that clear increases
in tyrosine phosphorylation of both IRS-1 and IRS-2, in p85
association, and in PI 3-K activity were observed at the lowest
insulin concentration tested (0.1 nm).
Effect of wortmannin on insulin-induced PK-L activation
When cultured hepatocytes were incubated for 10 min
with increasing concentrations of insulin, a significant dose-
dependent increment in the PK-L activity ratio (v0.15/Vmax)
was observed (by ANOVA, P , 0.0001; Fig. 2). It is well
established that the PK-L activity ratio is inversely related to
the degree of phosphorylation of the enzyme (18, 29). More-
over, in good agreement with other reports (23, 25), the
activation of PK-L by insulin was still evident after ammo-
nium sulfate precipitation of the enzyme (data not shown),
suggesting that a covalent change in the PK-L molecule (pos-
sibly dephosphorylation) occurs in response to insulin
(22–25).
To examine the role of PI 3-K in the activation of PK-L by
insulin, we used wortmannin, a well known inhibitor of PI
3-K activity (30). Thus, treatment of cultured hepatocytes
with 100 nm wortmannin completely abolished the activation
of PK-L caused by 0.1 nm insulin and decreased the hormonal
effects elicited by 1 and 10 nm insulin (reductions of 38% and
32%, respectively). When wortmannin was used at a con-
centration of 500 nm, the activation of PK-L was completely
blocked, even in the presence of saturating concentrations of
insulin (Fig. 2).
The differences in insulin-induced PK-L activation ob-
served in the presence of 100 and 500 nm wortmannin could
be related to distinct degrees of PI 3-K inhibition. To check
this possibility, PI 3-K activity was measured in anti-IRS-1
and anti-IRS-2 immunoprecipitates obtained from hepato-
cytes incubated with increasing concentrations of insulin in
the absence and presence of the inhibitor. As shown in Fig.
3, both 100 and 500 nm wortmannin strongly inhibited in-
sulin-dependent activation of PI 3-K associated with IRS-1
and IRS-2, at all of the assayed insulin concentrations. How-
ever, slight differences appeared to exist between residual PI
3-K activities found in hepatocytes incubated in the presence
of 100 and 500 nm wortmannin. To assess the consequence
of these slight differences in PI 3-K activity in steps of the
insulin signaling cascade downstream of this enzyme, we
examined the degree of phosphorylation of PKB on both
Thr308 and Ser473 residues, which is known to be dependent
on PI 3-K activation (5–7). As shown in Fig. 4A, cultured
hepatocytes incubated with different concentrations of in-
sulin for 5 min showed a dose-dependent increase in the
phosphorylation status of both Thr308 and Ser473 residues.
The presence of 100 nm wortmannin completely blocked the
phosphorylation of PKB elicited by 0.1 nm insulin. However,
FIG. 1. Influence of different concentrations of insulin on PI 3-K
activity associated with IRS-1 and IRS-2 in cultured rat hepatocytes.
Rat hepatocytes were cultured for 21 h as indicated in Materials and
Methods and were deprived of serum and hormones for the last 2 h.
Then cells were incubated with different concentrations of insulin for
5 min. Hepatocyte lysates were immunoprecipitated in duplicate with
either anti-IRS-1 or anti-IRS-2 antibodies. One sample of each im-
munoprecipitate was subjected to SDS-PAGE and Western blot anal-
ysis for IRSs, phosphotyrosine, and p85, and the other was used to
assay PI 3-K activity. Data are representative of two independent
experiments.
FIG. 2. Effect of wortmannin on insulin-induced activation of PK-L in
cultured rat hepatocytes. Rat hepatocytes were cultured for 21 h as
indicated in Materials and Methods and were deprived of serum and
hormones for the last 2 h. Then cells were preincubated for 10 min
with 100 (E) and 500 nM () wortmannin or vehicle (0.005% dimeth-
ylsulfoxide; F). Afterward, insulin was added at the indicated con-
centrations; 10 min later, cell monolayers were frozen and kept in
liquid nitrogen until PK-L activity was assayed. Results are the
mean 6 SEM (n 5 4 experiments). **, P , 0.01; ***, P , 0.001 (vs. the
corresponding vehicle incubations).
FIG. 3. Effect of wortmannin on insulin-induced activation of PI 3-K
associated with IRS-1 and IRS-2, in cultured rat hepatocytes. Rat
hepatocytes were cultured for 21 h as indicated in Materials and
Methods and were deprived of serum and hormones for the last 2 h.
Then cells were preincubated for 10 min with wortmannin or vehicle
(0.005% dimethylsulfoxide). Afterward, insulin was added at the in-
dicated concentrations; 5 min later, cell monolayers were immediately
homogenized. Cell extracts were immunoprecipitated with either an-
ti-IRS-1 or anti-IRS-2 antibodies. PI 3-K activity was assayed in the
immunoprecipitates. Data are representative of two independent ex-
periments.
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some residual PKB phosphorylation was detected in hepa-
tocytes treated with 1 and 10 nm insulin. When 500 nm
wortmannin was used, a complete suppression of both Thr308
and Ser473 phosphorylation was observed at all the assayed
insulin concentrations (Fig. 4B). A good direct correlation
appeared to exist between insulin-mediated PK-L activation
and the extent of PKB phosphorylation in the presence of 100
and 500 nm wortmannin.
Effect of wortmannin on insulin-induced MAPK activation
Although wortmannin has been widely considered as an
specific inhibitor of the PI 3-K signaling pathway (30), it has
been demonstrated that this agent can also reduce activation
of the MAPK pathway in different cellular systems (31, 32).
To examine whether this inhibitor does or does not affect the
MAPK pathway in cultured rat hepatocytes, we analyzed the
effect of wortmannin on the activation of this cascade by
insulin. For this purpose, cultured hepatocytes were incu-
bated with different concentrations of insulin for 5 min, and
MAPK activation was assessed using an antibody that only
recognizes the phosphorylated forms of ERK-1 and ERK-2.
As shown in Fig. 4, insulin increased the extent of phos-
phorylation of both ERK-1 and ERK-2 in a dose-dependent
manner. The effect on ERK-1 was far lower than that ob-
served on ERK-2; this is in agreement with the data reported
by Peak et al. (13), who found a barely detectable phosphor-
ylation and activation of ERK-1 in response to either insulin
or epidermal growth factor in rat hepatocytes. When cul-
tured hepatocytes were preincubated with 100 nm wortman-
nin, insulin-induced phosphorylation of ERK-1/ERK-2 was
partially inhibited (Fig. 4A), whereas it was completely abol-
ished, at all the assayed insulin concentrations, in hepato-
cytes treated with 500 nm wortmannin (Fig. 4B). All of these
findings indicate that in cultured rat hepatocytes wortman-
nin is a powerful inhibitor of both PI 3-K- and MAPK-
dependent pathways.
Effect of LY294002 on insulin-induced PK-L activation
To further support the involvement of PI 3-K in the acti-
vation of PK-L by insulin, LY294002, a PI 3-K inhibitor not
structurally related to wortmannin (3), was used. As shown
in Fig. 4C, treatment of cultured hepatocytes with LY294002
(50 mm) completely blocked the insulin-dependent activation
of the PI 3-K/PKB pathway at all of the assayed hormone
concentrations. When the influence of LY294002 on the
MAPK signaling pathway was tested (Fig. 4C), it was ob-
served that, in contrast to what occurred with wortmannin,
insulin-induced phosphorylation of ERK-1/ERK-2 was not
reduced, but even appeared to be increased. These results
were in good agreement with those reported by Zimmerman
and Moelling (33), who showed that the blockade of PKB
activation by LY294002 increased insulin-like growth factor
I-mediated activation of the MAPK cascade in HEK-293 and
MCF-7 cells.
When the influence of LY294002 on the insulin-dependent
activation of PK-L was studied, it was observed that 50 mm
FIG. 4. Effects of wortmannin, LY294002, and PD98059 on insulin-induced phosphorylation of PKB and p44/p42 MAPK (ERK-1/ERK-2), in
cultured rat hepatocytes. Rat hepatocytes were cultured for 21 h as indicated in Materials and Methods and were deprived of serum and hormones
for the last 2 h. Then cells were preincubated for 10 min with wortmannin, LY294002, or the corresponding vehicle as well as with PD98059
for 30 min. Afterward, different concentrations of insulin were added to the incubation medium, and 5 min later, cell monolayers were
immediately homogenized. Proteins from cell extracts were resolved by SDS-PAGE (50 mg protein/lane) and immunoblotted with anti-phospho-
PKB (Thr308 and Ser473) polyclonal antibodies, anti-phospho-p44/p42 MAP kinase (Thr202/Tyr204) monoclonal antibody, and anti-p44/p42
polyclonal antibody. Data are representative of at least two independent experiments.
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LY294002 significantly reduced the PK-L activity ratio in
hepatocytes incubated under basal conditions (0.168 6 0.012
vs. 0.105 6 0.014, for control and LY294002-treated hepato-
cytes, respectively; by paired Student’s t test, P , 0.001; n 5
4 experiments). This effect was not due to any interference of
LY294002 with the assay of PK-L activity (data not shown).
Furthermore, LY294002 clearly blocked the activation of
PK-L by subsaturating concentrations of insulin (0.1 nm). At
higher concentrations of hormone (1 and 10 nm), the PK-L
activity ratio increased, but to levels far below those reached
in hepatocytes incubated in the absence of LY294002 (Fig. 5).
Effects of PD98059 on insulin-induced MAPK
phosphorylation and PK-L activation
To evaluate the possible involvement of the MAPK path-
way in the insulin-induced activation of PK-L, PD98059 was
used. This organic compound is a specific inhibitor of the
MAPK pathway, which has been shown not to affect the
activation of PI 3-K by insulin in 3T3-L1 adipocytes (34).
Thus, cultured hepatocytes treated with PD98059 (50 mm)
showed a complete blockade of insulin-induced MAPK
phosphorylation at all of the assayed hormone concentra-
tions. Under these conditions, the activation of the PI 3-K/
PKB pathway by insulin was not affected (Fig. 4D).
When hepatocytes were incubated with 50 mm PD98095 in
the absence of insulin, a small, but statistically significant,
increase was observed in the basal PK-L activity ratio
(0.154 6 0.08 vs. 0.173 6 0.08 for control and PD98059-treated
hepatocytes, respectively; by paired Student’s t test, P , 0.05;
n 5 6 experiments; Fig. 6). We have no clear explanation for
this effect, but the presence of this inhibitor in the reaction
mixture did not interfere with the assay of PK-L activity (data
not shown). Nevertheless, as also shown in Fig. 6, PD98059,
at a concentration that completely blocked the MAPK cas-
cade (Fig. 4D), significantly reduced the activation of PK-L
elicited by saturating concentrations of insulin (1 and 10 nm).
Moreover, when insulin-induced PK-L activation was quan-
tified as a percentage of the respective basal value, a partial,
but statistically significant, reduction of the insulin effect was
observed at all of the assayed hormone concentrations in
hepatocytes treated with PD98059 (50%, 47%, and 45% re-
duction vs. the corresponding control incubations for 0.1, 1,
and 10 nm insulin, respectively; P , 0.001). The additional
presence of 100 nm wortmannin in the incubation medium
enhanced the inhibitory effect elicited by PD98059 on the
insulin-mediated activation of PK-L. This enhancement was
statistically significant at 0.1 and 1 nm insulin. All of these
findings suggest that both PI 3-K and MAPK pathways are
involved in the short-term activation of PK-L by insulin.
Effects of rapamycin on insulin-induced p70 S6-K
phosphorylation and PK-L activation
It has been established that stimulation of p70 S6-K activity
is dependent on PI 3-K activation (8). In connection with this,
previous reports have shown that the activation of p70 S6-K
by insulin in human myoblasts (35) and rat skeletal muscle
(12) takes several minutes and is preceded by PKB activation.
To study the possible involvement of p70 S6-K in the insulin-
induced activation of PK-L, we tested the influence of rapa-
mycin on this process. This macrolide is the most potent
inhibitor of p70 S6-K described to date, blocking the activa-
tion of this kinase by all known agents (36). First, we carried
out a time-course study of the insulin action on both PKB and
p70 S6 kinase activation in primary cultures of rat hepato-
cytes. As shown in Fig. 7A, maximal PKB phosphorylation
in response to 10 nm insulin was achieved as early as 2 min
after hormone treatment, and this kinase remained phos-
phorylated for at least 20 min. Nevertheless, phosphoryla-
tion of p70 S6-K on Thr389 residue, which is essential to bring
about full kinase activation (37), was barely detected 4 min
after insulin stimulation and increased gradually until min
FIG. 5. Effect of LY294002 on insulin-induced activation of PK-L in
cultured rat hepatocytes. Rat hepatocytes were cultured for 21 h as
indicated in Materials and Methods and were deprived of serum and
hormones for the last 2 h. Then cells were preincubated for 10 min
with 50 mM LY294002 (M) or vehicle (0.3% dimethylsulfoxide; F).
Afterward, insulin was added at the indicated concentrations; 10 min
later, cell monolayers were frozen and kept in liquid nitrogen until
PK-L activity was assayed. Results are the mean 6 SEM (n 5 4
experiments). ***, P , 0.001 vs. the corresponding basal incubations;
www, P , 0.001 vs. respective control incubations.
FIG. 6. Effect of PD98059 and wortmannin on insulin-induced acti-
vation of PK-L in cultured rat hepatocytes. Rat hepatocytes were
cultured for 21 h as indicated in Materials and Methods and were
deprived of serum and hormones for the last 2 h. Then cells were
preincubated with 50 mM PD98059 (30 min; E), 50 mM PD98059 (30
min) plus 100 nM wortmannin (10 min; ), or vehicle (0.6% dimeth-
ylsulfoxide; F) before the addition of insulin. Ten minutes later, cell
monolayers were frozen and kept in liquid nitrogen until PK-L ac-
tivity was assayed. Results are the mean 6 SEM (n 5 6 experiments).
**, P , 0.01; *, P , 0.05 (vs. corresponding control incubations). ww,
P , 0.01; w, P , 0.05 (vs. corresponding PD98059 incubations).
SIGNALING PATHWAYS OF PK-L ACTIVATION BY INSULIN 1061
 by on May 19, 2010 endo.endojournals.orgDownloaded from 
20 (Fig. 7A). As shown in Fig. 7B, the phosphorylation of p70
S6-K by insulin was also dose dependent and was completely
suppressed at all of the assayed hormone concentrations
when cultured hepatocytes were treated with 100 nm rapa-
mycin. Under these conditions, the phosphorylation of PKB
at Ser473 was not inhibited. As shown in Fig. 8, this same
concentration of rapamycin did not significantly affect the
activation of PK-L by insulin. These findings indicate that the
activation of p70 S6-K is not required for the insulin-depen-
dent activation of PK-L.
Discussion
It is well known that PK-L activity is modulated by phos-
phorylation/dephosphorylation of the enzyme molecule (18,
19). In liver, the phosphorylation and subsequent inactiva-
tion of PK-L can be mediated by cAMP- and Ca21-calmod-
ulin-dependent protein kinases (18, 19). However, there is no
agreement about the protein phosphatase(s) responsible for
the dephosphorylation and reactivation of PK-L (20–22).
With respect to the short-term modulation of PK-L activity
by insulin, it has been reported that this hormone may cause
the activation of this enzyme, without significant changes in
either cAMP levels or protein kinase A activity (23, 24). There
is experimental evidence supporting the hypothesis that the
stimulation of a protein phosphatase activity is implicated in
the regulation of PK-L by insulin (22, 23, 25). However, the
cellular signaling pathway leading to the short-term activa-
tion of PK-L by this hormone has not been established.
The PI 3-K/PKB signaling pathway has been shown to
play a central role in the modulation of glucose metabolism
by insulin. Thus, activation of this pathway has been shown
to mediate insulin effects on GLUT-4 translocation to the
plasma membrane in L6 myoblasts (11) as well as on the
activation of glycogen synthase and the stimulation of gly-
cogen synthesis in different cell types, including cultured
hepatocytes (12, 13). To investigate the possible involvement
of the PI 3-K-dependent signaling pathway in the insulin-
mediated activation of PK-L, wortmannin, a fungal metab-
olite that is a known inhibitor of PI 3-K activity (3, 30), was
used. Thus, 100 nm wortmannin totally suppressed the ac-
tivation of PK-L elicited by a subsaturating concentration of
insulin (0.1 nm), whereas the inhibitory effect of this agent
was only partial at 1 and 10 nm insulin. These findings were
paralleled by an inhibition of insulin-stimulated PI 3-K ac-
tivity and PKB phosphorylation, elicited by this concentra-
tion of wortmannin in cultured rat hepatocytes. When a
higher concentration of wortmannin (500 nm) was used, the
activation of PK-L was completely blocked at all of the as-
sayed insulin concentrations. Under these conditions, insulin
signaling through the PI 3-K/PKB pathway was totally sup-
pressed in cultured hepatocytes, as indicated by the complete
blockade of PKB phosphorylation. It is of note that PKB
phosphorylation on both Thr308 and Ser473 is a well known
PI 3-K-dependent process (5–7). All of these findings suggest
that the PI 3-K pathway is involved in the short-term acti-
vation of PK-L by insulin.
However, it must be mentioned that wortmannin has been
reported to reduce the activation of the MAPK cascade in
response to insulin in L6 cells (31), but not in human skeletal
muscle (38). Considering these controversial data, we also
investigated the possible influence of wortmannin on the
activation of the MAPK signaling pathway by insulin in
FIG. 7. Time course of insulin action on both PKB and p70 S6-K
phosphorylation (A) and influence of rapamycin on insulin-induced
PKB and p70 S6-K phosphorylation (B) in cultured rat hepatocytes.
A, Rat hepatocytes were cultured for 21 h as indicated in Materials
and Methods and were deprived of serum and hormones for the last
2 h. Then, cells were incubated with 10 nM insulin and homogenized
at the indicated times. Proteins from cell extracts were resolved by
SDS-PAGE (50 mg protein/lane) and immunoblotted with both anti-
phospho-PKB (Ser473) and anti-phospho-p70 S6-K (Thr389) polyclonal
antibodies. B, Rat hepatocytes were cultured for 21 h as indicated in
Materials and Methods and were deprived of serum and hormones for
the last 2 h. Then cells were preincubated for 10 min with 100 nM
rapamycin or vehicle. Afterward, insulin was added, and 10 min later,
cell monolayers were immediately homogenized. Proteins from cell
extracts were resolved by SDS-PAGE (50 mg protein/lane) and im-
munoblotted with both anti-phospho-PKB (Ser473) and anti-phospho-
p70 S6-K (Thr389) polyclonal antibodies. Data are representative of at
least two independent experiments.
FIG. 8. Effect of rapamycin on insulin-induced activation of PK-L in
cultured rat hepatocytes. Rat hepatocytes were cultured for 21 h as
indicated in Materials and Methods and were deprived of serum and
hormones for the last 2 h. Then cells were preincubated for 10 min
with 100 nM rapamycin (M) or vehicle (0.005% dimethylsulfoxide; F).
Afterward, insulin was added at the indicated concentrations, and 10
min later, cell monolayers were immediately frozen and kept in liquid
nitrogen until PK-L activity was assayed. Results are the mean 6 SEM
(n 5 4 experiments).
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cultured rat hepatocytes. We observed that at a concentration
of 100 nm, this inhibitor partially antagonized insulin effects
on the phosphorylation of ERK-1/ERK-2, whereas 500 nm
wortmannin completely suppressed these insulin effects.
Taking into account the fact that wortmannin was able to
inhibit both PI 3-K and MAPK pathways in cultured rat
hepatocytes, the wortmannin effect on insulin-mediated
PK-L activation could be due to the blockade of either of these
two pathways, or both. The mechanism by which wortman-
nin inhibits the MAPK pathway is not well understood; it has
been suggested that this agent may block the activation of
this pathway between Ras and Raf in L6 cells (31), whereas
a decrease in GTP loading of Ras has been observed in 3T3L1
adipocytes (39).
To further investigate the involvement of PI 3-K in insulin-
induced PK-L activation, LY294002, a selective PI 3-K inhib-
itor, was used. In our cell system, this inhibitor blocked
insulin signaling through the PI 3-K/PKB pathway, and in
contrast to the results obtained with wortmannin, LY294002
did not reduce but, rather, increased the insulin effect on the
MAPK cascade. In this respect it has been demonstrated in
different types of cells that the activation of PKB results in Raf
phosphorylation on Ser259, which reduces its kinase activity
and consequently the activation of the p44/p42 MAPK path-
way (33, 40). Furthermore, inhibition of PKB activation by
LY294002 has been shown to increase Raf and ERK activities
in HEK 293 and MCF-7 cells (33). Our results suggest that this
cross-regulation between PI 3-K/PKB and MAPK pathways
may also occur in cultured hepatocytes.
When the influence of LY294002 on insulin-induced PK-L
activation was investigated, it was observed that this inhib-
itor, in contrast to what occurred with wortmannin, caused
a significant reduction in the PK-L activity ratio in hepato-
cytes incubated in the absence of insulin, although we have
no clear explanation for this phenomenon. In hepatocytes
treated with a subsaturating concentration of insulin (0.1
nm), LY294002 almost completely blocked the activation of
PK-L, whereas at higher concentrations of insulin (1 and 10
nm), the effect of LY294002 was markedly reduced. However,
in these conditions the values for the PK-L activity ratio
attained in response to insulin were far lower than those
reached in control hepatocytes. From these data and from the
studies carried out with wortmannin, it can be concluded
that the PI 3-K signaling pathway is implicated in the short-
term activation of PK-L by insulin. In addition, it must be
pointed out that the difference between the degrees of inhi-
bition of insulin-mediated PK-L activation elicited by 500 nm
wortmannin and 50 mm LY294002 may have been due to the
fact that wortmannin at this concentration blocked the acti-
vation of the MAPK cascade, whereas LY294002 did not.
p70 S6-K is an enzyme that lies downstream of PI 3-K in
the insulin signaling pathway (9). In previous studies (12, 13),
rapamycin, a potent inhibitor of this kinase, has been used to
study the possible involvement of p70 S6-K in the regulation
of glycogen synthase activity by insulin. In our work we
observed that 100 nm rapamycin, a concentration that com-
pletely blocked the phosphorylation of p70 S6-K in Thr389,
did not significantly affect insulin-mediated activation of
PK-L in cultured rat hepatocytes. This finding allows us to
rule out the implication of this kinase in the signaling cascade
that leads to the short-term activation of PK-L by insulin.
To analyze the possible involvement of the p44/p42
MAPK cascade in the activation of PK-L by insulin, PD98059
was used. Thus, we observed that 50 mm PD98059, which
completely blocked ERK-1/ERK-2 phosphorylation without
affecting PI 3-K/PKB activation, led to a 50% inhibition of the
insulin-induced activation of PK-L. This finding strongly
suggests that the activation of the p44/p42 MAPK pathway
plays a relevant role in the short-term activation of PK-L by
insulin. The additional presence of 100 nm wortmannin in the
incubation medium significantly reinforced the inhibitory
effect of PD98059 on insulin-induced activation of PK-L. As
the signal transduction through the MAPK pathway was
completely suppressed by the presence of PD98059, this
wortmannin action must be attributed to the partial inhibi-
tion of PI 3-K elicited by this agent. In good agreement with
this, when both the PI 3-K and MAPK pathways were com-
pletely blocked by the presence of 500 nm wortmannin, ac-
tivation of PK-L by insulin was totally suppressed.
The activation of the PI 3-K/PKB pathway has been shown
to be essential for most of the metabolic actions of insulin (3),
whereas the MAPK cascade has been considered to be im-
plicated mainly in mitogenic signals (10). Nevertheless, re-
cent reports have affirmed that both pathways are involved
in different actions of insulin and insulin-like growth factor
I, such as protection of cells from apoptosis (41), stimulation
of protein synthesis (42), and regulation of insulin receptor
trafficking (43). Moreover, cross-talk between the PI 3-K and
MAPK pathways has been reported at different levels in
several cell systems (33, 39, 40, 44), suggesting that integra-
tion of signals through different pathways is crucial for the
coordinated responses of cells to hormonal stimuli.
In summary, our findings provide evidence that both p44/
p42 MAPK and PI 3-K pathways, but not p70 S6-kinase, are
involved in the short-term activation of PK-L by insulin.
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